RELEASE: SHL Medical and Lifecore Biomedical enter into joint marketing partnership agreement

ZUG, Switzerland, Oct.

RELEASE: SHL Medical and Lifecore Biomedical enter into joint marketing partnership agreement

ZUG, Switzerland, Oct. 17, 2023/PRNewswire/ -- SHL Medical ("SHL"), a leading global provider of advanced medication delivery system solutions, including auto-injectors and innovative specialized delivery systems, has entered into a non-exclusive joint marketing partnership with Lifecore Biomedical (Nasdaq: LFCR) ("Lifecore"), a fully integrated Contract Development and Manufacturing Organization ("CDMO") offering highly differentiated capabilities in the development, filling and finishing of pharmaceutical products complex sterile injectables in syringes and vials.

Through this partnership, Lifecore becomes a member of SHL's recently announced Alliance Management program, an initiative created to further strengthen SHL's vertically integrated business model by facilitating customer interaction with other key players within the delivery ecosystem. of medications.

SHL and Lifecore, in accordance with the terms of their agreement, will exchange knowledge and experience in their respective fields, allowing both companies to provide their clients with unparalleled guidance in CDMO services and the best options for the development of management devices. medicines.

As a leader and pioneer of autoinjectors, SHL offers medication delivery device solutions and vertically integrated capabilities for the development, manufacturing and final assembly of its autoinjector products. The partnership with Lifecore will enable SHL to recommend a reliable CDMO recognized for its proven competence and robust quality systems in aseptic pharmaceutical manufacturing and primary container filling, creating a comprehensive support system at all stages of autoinjector and product development. commercial life cycle.

"As a true partner to the pharmaceutical and biotechnology industry, we believe in providing comprehensive solutions that improve the quality of life of patients and enable their independence," said Kimberlee Steele, CEO of SHL Pharma, final assembly, labeling and manufacturing business unit. SHL Medical packaging in Florida. "We are excited to partner with Lifecore to provide high-quality CDMO services that match SHL's high-touch approach to serving our customers."

Darren Hieber, senior vice president of corporate development and partnerships at Lifecore commented: "We continually adapt to keep pace with the evolution of healthcare treatments and technologies and our deep experience in filling and finishing syringes and vials is a perfect match. for SHL products. Our relationship with SHL will expand the breadth of our offerings to our CDMO customers, allowing them to offer the benefits and convenience of innovative medication delivery systems to their patients around the world. We are excited to be aligned with an industry leader, who has created a company focused on patient-centered solutions through its unique, convenient and high-quality product portfolio."

- The image is available in AP -

About SHL MedicalAs a leading global provider of advanced drug delivery system solutions, SHL Medical is the partner of choice for many leading pharmaceutical and biotechnology companies. Driven by its company purpose: enabling patient independence, SHL Medical offers patient-centric solutions for the design, development and manufacturing of autoinjectors, pen injectors, as well as innovative specialized delivery systems for high-volume formulations and high viscosity. It also offers final assembly, labeling and packaging solutions for its medication delivery systems.

In response to the growing trend of home therapy, SHL Medical has increased its development work in the digital healthcare sector to help improve the medication management ecosystem.

Located in Switzerland, Taiwan, Sweden and the US, SHL Medical's global team of experts collaborate seamlessly as a single team using its comprehensive in-house manufacturing capabilities. The company's solutions offer customization and optimization for each project, while proactively incorporating sustainability-driven measures into its designs and processes to contribute to a cleaner earth. For additional information, visit

About Lifecore BiomedicalLifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) offering highly differentiated capabilities in the development, filling and finishing of complex sterile injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium injectable grade hyaluronic acid, Lifecore brings more than 40 years of experience as a partner to global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the Company, please visit Lifecore's website at

Media ContactCarl GillbladCommunications and Marketing 41 41 368 00 00

Alliance Management Contact Alina SmotrovaBusiness 41 41 368 00 00

Lifecore Investor Relations Jeff 277-1263

Forward-Looking StatementsThis press release contains forward-looking statements regarding future events and future results, including the anticipated business relationship between SHL and Lifecore, which are subject to statements made under the Private Securities Litigation Reform Act of 1995 and others under the Securities of 1933 and the Securities Exchange Act of 1934. Words like "anticipate," "estimate," "expect," "project," "plan," "intend," "believe," "may," "could" , "will", "should", "may", "likely" and similar expressions are used to identify forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors, but not limited to, the nature and requirements of the relationship between SHL and Lifecore, the ability to achieve acceptance of new products from Lifecore in the market, and government regulations affecting the companies' respective businesses. For additional information on factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to Lifecore's filings with the Securities and Exchange Commission, including the risk factors contained in our most recent Quarterly Report at Form 10-Q and Annual Report on Form 10-K/A. Forward-looking statements represent management's current expectations and are inherently uncertain. Except as required by law, neither company undertakes any obligation to update any forward-looking statements made to reflect subsequent events or circumstances.

Photo -

View original content: